Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 52 (TRAJ52) is a genomic DNA segment that encodes one of the joining (J) elements used during the somatic recombination of T cell receptor (TCR) alpha chains in developing T lymphocytes[1][4][7][2]. It is not a protein target in the usual therapeutic sense, nor is it expressed independently; instead, it serves as one of the modular gene segments (joined with V and C regions) to generate the immense diversity of antigen-specific alpha chains comprising mature TCRs on T cell surfaces[1][2][6]. TRAJ52 itself is not directly targeted by drugs, is not a traditional receptor or enzyme, and does not act as a standalone molecule. Rather, its sequence contributes to the overall diversity of TCRs, which are essential for immune recognition. TRAJ52 is not considered a therapeutic target; its clinical or functional relevance comes only from its participation in the broader process of TCR assembly and the adaptive immune response[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 52 (TRAJ52).